Nxstage Medical, Inc. (NXTM) Files Form 4 Insider Selling : Joseph E Jr Turk Sells 1,500 Shares

Nxstage Medical, Inc. (NXTM): Joseph E Jr Turk , President of Nxstage Medical, Inc. sold 1,500 shares on May 12, 2016. The Insider selling transaction was reported by the company on May 12, 2016 to the Securities and Exchange Commission. The shares were sold at $17.89 per share for a total value of $26,835.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on May 11, 2016, Joseph E Jr Turk (President) sold 1,057 shares at $18.00 per share price.On Apr 15, 2016, Jeffrey H Burbank (Chief Executive Officer) sold 10,000 shares at $16.21 per share price.Also, On Apr 15, 2016, Winifred L Swan (SVP and General Counsel) sold 6,260 shares at $16.56 per share price.On Jan 11, 2016, Matthew W Towse (SVP and Chief Financial Office) sold 3,472 shares at $20.40 per share price.

NxStage Medical: On Tuesday, May 10, 2016 heightened volatility was witnessed in NxStage Medical which led to swings in the share price. The shares opened for trading at $17.97 and hit $18.285 on the upside , eventually ending the session at $18, with a gain of 0.61% or 0.11 points. The heightened volatility saw the trading volume jump to 6,04,138 shares. The 52-week high of the share price is $22.6 and the company has a market cap of $1,159 M . The 52-week low of the share price is at $13.47.

NxStage Medical Money Flow Index Chart

Company has been under the radar of several Street Analysts.NxStage Medical is Resumed by Piper Jaffray to Overweight while Lowering the Price Target of the company shares to $ 18.50 from a previous price target of $23 . The Rating was issued on Mar 31, 2016.

NxStage Medical Inc. is a medical device company. The Company is engaged in the development manufacturing and marketing of products for the treatment of kidney failure fluid overload and related blood treatments and procedures. The Company’s products include the System One Streamline Blood Tubing Sets and AV Fistula and Apheresis Needles. Its primary product the System One is a small portable easy-to-use hemodialysis system. It is designed to deliver the therapeutic flexibility and clinical benefits associated with traditional dialysis machines in a smaller portable easy-to-use form that can be used by healthcare professionals and trained lay users alike in a variety of settings including patient homes as well as more traditional care settings such as hospitals and dialysis centers. The Company operates in three reportable business segments: System One In-Center and Services.

Leave a Reply

NxStage Medical - Is it time to Sell?

Top Brokerage Firms are advising their investors on NxStage Medical. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.